| Literature DB >> 35466272 |
Matteo Mario Carlà1,2, Francesco Boselli1,2, Federico Giannuzzi1,2, Gloria Gambini1,2, Tomaso Caporossi1,2, Umberto De Vico1,2, Alfonso Savastano1,2, Antonio Baldascino1,2, Clara Rizzo3, Raphael Kilian3, Stanislao Rizzo1,2.
Abstract
Myopia is becoming more common across the world, affecting approximately two billion people and rising. Different kinds of therapies (optical, pharmaceutical, environmental, or behavioral) have been proposed to decrease myopia progression, but with variable results and a lack of standardization. The evidence that targeted myopic defocus inhibits eye length growth has paved the way for several contact and spectacle lense designs to induce a peripheral defocus, thus slowing myopia progression, but the perfect configuration has yet to be defined. One of the newest and more promising approaches in this field is the use of Defocus Incorporated Multiple Segments (DIMS) lenses. These lenses are built from the assumption that targeted myopic defocus, produced by 396 mid-peripheral lenslets with positive power, inhibits eye length growth. Recent studies have highlighted the effectiveness of these lenses compared to children who had worn single vision spectacle lenses, in terms of myopia control and tolerability. Despite the evidence that these lenses can help slow down the progression of myopia, the occasional mid-peripheral aberrations they can induce, as well as the overall eye strain that comes with wearing them, should not be overlooked. The aim of this review is to give attention to the advantages and the shortfalls of this new approach and to evaluate its effectiveness in clinical practice.Entities:
Keywords: DIMS; defocus incorporated multiple segments; myopia; myopia control; myopic defocus; peripheral defocus; relative peripheral refraction; spectacle lens
Year: 2022 PMID: 35466272 PMCID: PMC9036268 DOI: 10.3390/vision6020020
Source DB: PubMed Journal: Vision (Basel) ISSN: 2411-5150
Figure 1The design of the Defocus Incorporated Multiple Segments (DIMS) MiYOSMART spectacle lens. Available online: www.hoyavision.com (accessed on 30 December 2021).
Figure 2Optical principles of DIMS lens. The blue lines represent ray traces from the central (carrier) part of the lens, which form a clear image on the retina [a], while the red lines represent ray traces from the peripheral part of the lens, containing the lenslets, which form an image that is refracted by both the base part and the lenslets simultaneously [b]. The picture [c] or [d] will be generated on the retina if the target is close and the eye does not accommodate. An object located on the central axis generates a crisp image with no ghosting, while seeing a target via the peripheral section of the lens causes ghosting, depending on the relative refractive error at the retina as described in [c] or [d] [Image taken from Lam et al. “Effect of Defocus Incorporated Multiple Segments Spectacle LensWear on Visual Function in Myopic Chinese Children”] [71].
Clinical studies on myopia progression management. BF, bifocal spectacle lens; COMET2 and PEDIG, Correction of Myopia Evaluation Trial 2 Study Group and the Pediatric Eye Disease Investigator Group; DF, dual-focus contact lens; DISC, Defocus Incorporated Soft Contact; MD, myopic defocus; PAL, progressive addition lens; SV CL, single vision contact lens; SVL, single vision spectacle lens; DIMS, Defocus Incorporated Multiple Segments.
| Treatment Effect in Retarding Myopia Progression over the Study Period | ||||||
|---|---|---|---|---|---|---|
| Study | Period (Months) | Age | Criteria of Rx (D) | Type of Interventions and Sample Size | Mean Difference in D (%) | Mean Difference in mm of AL (%) |
| Gwiazda et al. (2003) [ | 36 | 6–11 | −1.25 to −4.5 | SVL, | −0.20 (14%) | −0.11 (15%) |
| Hasebe et al. (2008) [ | 18 | 6–12 | −1.25 to −6 | SVL, | −0.31 (18%) | - |
| COMET2 and PEDIG (2011) [ | 36 | 8–12 | −0.75 to −2.50 | SV, | −0.28 (24%) | - |
| Anstice and Phillips | 1st: 10 | 11–14 | −1.25 to −4.5 | SV CL, | 1st: −0.25 (37%) | 1st: −0.11 (49%) |
| Sankaridurg et al., | 12 | 7–14 | −0.75 to −3.5 | SVL, | −0.29 (34%) | −0.13 (33%) |
| Lam et al. (2014) [ | 24 | 8–13 | −1 to −5 | SV CL, | −0.21 (25%) | −0.11 (30%) |
| Chamberlain et al. (2019) [ | 36 | 8–12 | −0.75 to −4 | SV, | −0.73 (59%) | −0.32 (52%) |
| Walline et al. (2020) [ | 36 | 7–11 | −0.75 to −5 | SV, | −0.46 (43%) | −0.23 (36%) |
| Lam et al. (2020) [ | 24 | 8–13 | −1 to −5 | SV, | −0.55 (52%) | −0.32 (62%) |
| Lam et al. (2021) [ | 12 (3rd year of previous trial) | 10–15 | −1 to −5 | Control group, | −0.30 (86%) | −0.12 (61%) |